First patient enrolled in third Phase III study of oral laquinimod for relapsing-remitting multiple sclerosis Teva Pharmaceutical Industries Ltd., 6 Mar 2013 Accessed on 13 Mar 2013 from http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1792853. CommentRecommendBookmarkWatch